TSRIP / Tumor State Research Intelligence Platform
That is where TSRIP begins. Instead of starting with familiar drug pairs or asking only whether two agents are synergistic, TSRIP is being designed to uncover unexpected combination opportunities from the biological states that treatment creates or selects.
The first treatment may suppress one pathway while revealing a new dependency, activating an escape mechanism, or leaving a vulnerable residual cell population. TSRIP seeks the next intervention from that changed state.
TSRIP is a separate computational research platform in development. Its hypotheses are intended for experimental testing, not statements of demonstrated efficacy.
The TSRIP starting point
01 / Drug A
Target engagement, cell death, adaptation, immune effects or incomplete exposure.
02 / Tumor after treatment
Residual disease, bypass signaling, induced dependencies and spatially distinct survival.
03 / Drug B opportunity
A mechanistically justified intervention, sequence or delivery strategy to test.
Conceptual discovery sequence — not an observed clinical result or validated drug combination.
A different discovery question
TSRIP starts with a time-resolved account of how treatment transforms the tumor. Conventional synergy and target-complementarity studies may be useful later, but they are not the organizing starting point of this research approach.
Conventional combination starting points
Many combination programs begin with known targets, pathway maps, drug-pair screening or simultaneous-treatment synergy measurements.
Starting question: Do Drug A and Drug B have complementary effects?
TSRIP's proposed starting point
Follow the causal consequences of an intervention: what it suppresses, what survives, what compensates, when these changes appear and where residual disease persists.
Starting question: Which new or previously overlooked vulnerability becomes actionable after treatment?
Treatment-history-aware discovery
TSRIP is designed to distinguish what treatment induces from what treatment selects, and to trace how each change may create a testable biological opportunity.
01 / INTERVENTION
Mechanism, dose/exposure, line of treatment, disease state and tissue location.
02 / TRANSFORMATION
Downstream consequences, feedback, bypass, persistence, immune and stromal changes.
03 / OPPORTUNITY
Discover mechanisms and pathways that become relevant specifically in the new tumor state.
04 / FALSIFICATION
Compare concurrent and sequential hypotheses, controls, biomarkers and the smallest discriminating test.
Where unexpected opportunities arise
TSRIP systematically explores therapeutic consequences that may not be obvious from either drug's established indication or primary mechanism alone.
Feedback & bypass
Drug pressure may trigger compensatory signaling or expose an alternate dependence. TSRIP investigates whether that response creates a new intervention opportunity.
Residual tumor state
Persister populations, altered immune environments, stromal protection and regional underexposure may explain what survives the first treatment.
Sequence & location
Drug A then B, B then A, concurrent dosing or altered delivery can represent different hypotheses. TSRIP is designed to compare them rather than assume simultaneity.
Illustrative question
Imagine Drug A suppresses its target, but the surviving tumor cells become dependent on another pathway. The opportunity may be to exploit that post-treatment dependence with Drug B at the right time—rather than to mix A and B solely because a simultaneous assay suggests synergy.
Does Drug A actually create or select the proposed state? Does Drug B preferentially affect that state? Is A → B more effective than B → A or concurrent exposure under biologically relevant conditions?
From computational discovery to experimental reality
TSRIP is being designed to translate ranked tumor-state hypotheses into research plans that qualified laboratories can execute—not leave them as theoretical pairings.
Where a concept warrants development, we can coordinate actual wet-lab feasibility and formulation work through CDMO collaborators, subject to project-specific engagement and technical assessment.
Research-to-development pathway
TSRIP can propose a biological intervention, assess whether a shared formulation is physically plausible when relevant, and outline the measurements required before a development decision.
Qualified CDMO collaborators may then undertake the corresponding laboratory work, including feasibility studies, prototype formulation and analytical characterization where suitable.
CDMO work requires agreed scope, capabilities, contracting and independent experimental validation. No specific product or collaboration is represented as completed.
Two separate platforms
TSRIP · Tumor State Research Intelligence Platform
Drug-agnostic discovery of tumor-state-dependent combination, sequencing and delivery hypotheses, translated into experimentally testable development plans.
TSCIP · Tumor State Combination Intelligence Platform
Selective clinical asset origination, buyer-centric intelligence and hands-on business development support where needed to advance partnering discussions.
TSRIP is in development. Mechanistic plausibility does not establish synergy, clinical benefit, safety, compatibility or feasibility of co-formulation. Proposed ideas require independent testing, development and appropriate regulatory evaluation.
TSRIP research discussions
For research groups, pharmaceutical innovators and potential laboratory collaborators interested in tumor-state-driven combination discovery and experimental development.